Strategy

April 29, 2020

Dealing with significant unplanned events in alliances is important work. It's is critical to maintain the ongoing health of the alliance by applying sound governance principles and minimizing the disruption to normal operations wherever possible. So how can you stabilize your ships in rough seas?

April 24, 2020

Across all pharma companies' activities, the COVID-19 crisis has reinforced the need for pharma leaders to commit to, communicate, and exemplify the purpose that is at the center of their strategies and organizations.

April 18, 2020

Bill Barr outlines the systematic application of three criteria to guide discounting decisions.

April 17, 2020

Donna L. LaVoie discusses four key industry areas that will experience downstream pressures in the wake of the COVID-19 crisis.

April 08, 2020

In 2020 and beyond, succeeding in the new ecosystem means focusing on delivering value backed by data, tailored engagements with a diverse range of distinctly defined stakeholders, and monitoring the rapidly evolving healthcare space for new trends that will impact success.

March 06, 2020

Wolfram Lux and Simon Seiter discuss the implications of Strategic Market Access on work and processes, and its role in product planning and drug development success.

October 18, 2019

Mike Kean and Billy Tamulynas discuss the key components of growth-ready technology for early-stage pharma companies and how to make optimal use of them.

September 13, 2019

To ensure patients have timely access to expensive new therapies, biopharma companies have to address commercialization challenges with innovative measures, even after getting regulatory approval.

July 08, 2019

While culture may "eat" strategy, shared understanding creates both culture and strategy, write Steve Figman and Sean Robertson.

May 20, 2019

Pharmaceutical Executive

Creating an IP portfolio strategy that includes R&D, in-licensing, out-licensing, and mergers and acquisitions can help businesses stay ahead of the competition.